Dexcom’s CEO Kevin Sayer has shared new data on the company’s first over-the-counter glucose sensor at the recent J.P. Morgan Healthcare Conference in America earlier in January.
Stelo, an over-the-counter glucose monitor for people with Type 2 diabetes who don’t take insulin, was launched in August 2024 and had about 140,000 users by the end of the year. The US Food and Drug Administration cleared the device to make it available for adults with prediabetes or for general wellness purposes. Sayer told MedTech Dive that Dexcom initially saw more Stelo purchases from health and wellness users “because these people wanted it really bad,” before seeing more uptake from people with Type 2 diabetes and prediabetes.
Sayer said having a 15-day sensor is important because users and physicians prefer a longer wear time, and it reduces Dexcom’s cost of goods. Currently, Dexcom’s G7 is indicated for a ten-day wear time.
As for Stelo, Sayer said a partnership with Ōura, the maker of a smart ring, will allow users to bring sleep data to the platform. Dexcom also plans to add integrations with meal-tracking apps such as MyFitnessPal in response to user feedback.
In addition, the company has begun work on a next-generation CGM. Sayer said the sensor will be smaller, less expensive and include better electronics. Dexcom is also studying new sensor probes, one of which can support multiple analytes, such as measuring lactate or ketones in addition to insulin.
To find out more, CLICK HERE.
